Sandoz Group AG (SDZNY)

OTCMKTS · Delayed Price · Currency is USD
42.96
+0.75 (1.78%)
Mar 28, 2025, 3:58 PM EST
46.17%
Market Cap 18.52B
Revenue (ttm) 10.38B
Net Income (ttm) n/a
Shares Out n/a
EPS (ttm) n/a
PE Ratio n/a
Forward PE n/a
Dividend 0.53 (1.23%)
Ex-Dividend Date Apr 22, 2025
Volume 6,157
Average Volume 37,893
Open 42.11
Previous Close 42.21
Day's Range 42.11 - 43.12
52-Week Range 27.79 - 49.81
Beta n/a
RSI 46.91
Earnings Date Mar 5, 2025

About Sandoz Group AG

Sandoz Group AG develops, manufactures, and markets generic pharmaceuticals and biosimilars worldwide. The company covers therapeutic areas, including cardiovascular, central nervous system, oncology, infectious diseases, pain and respiratory, diabetes, immunology, endocrinology, hematology, and ophthalmology. It also provides a portfolio of active pharmaceutical ingredients and finished dosage forms. The company was founded in 1886 and is headquartered in Basel, Switzerland. [Read more]

Sector Healthcare
Founded 1886
Employees 22,049
Stock Exchange OTCMKTS
Ticker Symbol SDZNY
Full Company Profile

Financial Performance

Financial Statements

News

Sandoz signs landmark supply and manufacturing agreement

BOUCHERVILLE, Quebec, March 18, 2025 (GLOBE NEWSWIRE) -- Sandoz Canada, the leader in generic and biosimilar medicines in Canada, has signed a 10-year, long-term supply agreement with its partner Delp...

13 days ago - GlobeNewsWire

Thanks to $60 Million Federal Investment - DELPHARM TO MODERNIZE ITS FACILITIES AND ENSURE CONTINUED PRODUCTION OF STERILE INJECTABLE MEDICINES IN BOUCHERVILLE

BOUCHERVILLE, QC , March 18, 2025 /CNW/ - Delpharm, a world leader in pharmaceutical outsourcing, announced that it has reached an agreement with the Government of Canada to modernize its injectable m...

13 days ago - Benzinga

Sandoz Group AG (SDZNY) (Q4 2024) Earnings Call Highlights: Record Sales and Strategic Growth ...

Sandoz Group AG (SDZNY) (Q4 2024) Earnings Call Highlights: Record Sales and Strategic Growth Initiatives

25 days ago - GuruFocus

US Tariffs Will Raise Drug Prices for Patients, Sandoz CEO Says

The US shift toward steep tariffs will likely make drugs more expensive and limit access for patients, according to one of the world’s largest makers of generic medicines.

26 days ago - Financial Post

Health Care Roundup: Market Talk

Find insight on Bayer, Sandoz, Fresenius and more in the latest Market Talks covering Health Care.

26 days ago - The Wall Street Journal

Sandoz reports strong FY 2024 results and Q4 2024 sales

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE FY 2024 net sales[1] of USD 10.4 billion, up by 9%[2] in constant currencies (+7% in USD); Q4 net sales of USD 2....

26 days ago - GlobeNewsWire

Avecho and Sandoz enter exclusive license and development agreement to commercialise CBD for insomnia in Australia

Highlights: Avecho and Sandoz sign an exclusive ten-year development and license agreement ("Agreement") for Avecho's pharmaceutical cannabidiol capsule for insomnia in Australia Avecho to receive upf...

27 days ago - PRNewsWire

Sandoz family foundation offers $3 billion worth of Novartis shares

Emasan AG, an arm of the Sandoz Family Foundation, has launched a public offering of some 26.5 million shares in Swiss pharmaceutical firm Novartis to raise up to $3 billion in an accelerated bookbuil...

4 weeks ago - Reuters

NHS England's Transition From Biogen's Drug To Sandoz's Biosimilar Sparks Alarm As Multiple Sclerosis Patients Report Severe Effects

A cost-saving effort by NHS England to transition multiple sclerosis (MS) patients from Biogen Inc’s (NASDAQ: BIIB) Tysabri (natalizumab) to the biosimilar drug Tyruko has led to significant side eff...

5 weeks ago - Benzinga

MS patients suffer side-effects after NHS England switches to cheaper drug

Scores of people experience complications after change from Tysabri to Tyruko as part of NHS drive to save money ‘It was awful for me’: one MS patient shares her experience with Tyruko Scores of peopl...

5 weeks ago - The Guardian

Sandoz launches biosimilar Pyzchiva® (ustekinumab-ttwe) in the US, offering new treatment for around 12 million patients[1-4]

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules Key biosimilar value driver contributes to Sandoz global growth strategy and moves company closer to becoming #1 in biosimilars...

5 weeks ago - GlobeNewsWire

Francisco Ballester to retire; Peter Stenico appointed President Region International

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules President Region International, Francisco Ballester, to retire as of March 1, 2025, after 34 years of service Peter Stenico, cu...

2 months ago - GlobeNewsWire

Sandoz to confirm strategic roadmap and highlight pipeline catalysts at 43rd Annual J.P. Morgan Healthcare Conference

MEDIA RELEASE Strong first year as standalone company; global leader Sandoz uniquely positioned in attractive and growing USD 200 billion market for generics and biosimilars Leading in home market Eur...

2 months ago - GlobeNewsWire

Intra-Cellular Therapies Stock Soars 19% After Securing Major Patent Victory Over Sandoz

Intra-Cellular Therapies Stock Soars 19% After Securing Major Patent Victory Over Sandoz

2 months ago - GuruFocus

Intra-Cellular settles Caplyta patent dispute with Sandoz

Intra-Cellular Therapies (ITCI) stock jumps as the company settles a patent dispute with Sandoz (SDZNY) over Caplyta. Read more here.

2 months ago - Seeking Alpha

Intra-Cellular Therapies Inc (ITCI) Announces Settlement with Sandoz Over CAPLYTA Patent Litigation

Intra-Cellular Therapies Inc (ITCI) Announces Settlement with Sandoz Over CAPLYTA Patent Litigation

2 months ago - GuruFocus

Caplin Point gets USFDA approval for eye drops – Difluprednate Ophthalmic Emulsion

Caplin Point Laboratories announced receiving final approval from the US Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Difluprednate Ophthalmic Emulsion 0.05...

3 months ago - Business Upturn

Sandoz Charts Path to Swift Generic Ozempic Launch in Canada

Sandoz Group AG plans to use the Canadian market as a trial balloon for generic Ozempic, challenging Novo Nordisk A/S with a copycat version as soon as 2026.

3 months ago - Financial Post

Sandoz Charts Path to Swift Generic Ozempic Launch in Canada

Sandoz Group AG plans to use the Canadian market as a trial balloon for generic Ozempic, challenging Novo Nordisk A/S with a copycat version as soon as 2026.

3 months ago - BNN Bloomberg

Glenmark Pharmaceuticals shares in focus as company launches Travoprost Ophthalmic Solution in U.S.

Glenmark Pharmaceuticals Inc., USA, headquartered in Mahwah, New Jersey, has announced the launch of Travoprost Ophthalmic Solution USP, 0.004% (Ionic Buffered Solution), marking a significant additio...

4 months ago - Business Upturn

Glenmark Pharmaceuticals USA launches Travoprost Ophthalmic Solution USP

Glenmark Pharmaceuticals Inc., USA, headquartered in Mahwah, New Jersey, has announced the launch of Travoprost Ophthalmic Solution USP, 0.004% (Ionic Buffered Solution). This product is a bioequivale...

4 months ago - Business Upturn

Agomab Announces the Appointment of Former Sandoz CFO Colin Bond to its Board of Directors

ANTWERP, Belgium--(BUSINESS WIRE)--Agomab Therapeutics NV (‘Agomab') today announced the appointment of Colin Bond to the company's Board of Directors as a non-executive Director and Chairman of the A...

4 months ago - Business Wire